Welcome to our dedicated page for DexCom news (Ticker: DXCM), a resource for investors and traders seeking the latest updates and insights on DexCom stock.
DexCom, Inc. (DXCM) is a leading medical device company founded in 1999, specializing in continuous glucose monitoring (CGM) systems. These systems provide a significant advancement over traditional blood glucose meters, offering real-time glucose readings for diabetic patients. DexCom's innovative CGM technology empowers patients and clinicians to better manage diabetes, contributing to improved health outcomes.
DexCom's flagship products include the Dexcom G6 and the newly developed Dexcom G7 CGM systems. These devices offer features such as customizable alerts, seamless app integration, and data sharing capabilities. The company is also working on integrating their CGM systems with insulin pumps from Insulet and Tandem Diabetes Care, Inc., enabling automatic insulin delivery for more efficient diabetes management.
Recent achievements include the expansion into international markets and the continuous enhancement of their product lineup through research and development. Financially, DexCom has shown robust growth with increasing revenues and solid market performance, reflecting the growing demand for advanced diabetes management solutions.
The company has established strategic partnerships with key players in the medical device industry, further enhancing their market presence and technological capabilities. DexCom is committed to innovation, patient empowerment, and improving the quality of life for people with diabetes worldwide.
DexCom, the leader in continuous glucose monitoring, has launched its first-ever Super Bowl commercial featuring Nick Jonas. Airing on February 7, 2021, the ad emphasizes the need for better diabetes care and aims to increase awareness about the Dexcom G6 CGM system, which eliminates painful finger pricks. The commercial highlights the outdated finger-prick method still used by millions of diabetics. DexCom plans to partner with diabetes nonprofits to promote better access to CGM technology.
DexCom, Inc. (NASDAQ:DXCM) is set to release its fourth quarter and full year 2020 financial results on February 11, 2020, after market close. A conference call will follow at 4:30 p.m. ET, available via webcast on the investor relations website. This release marks a significant opportunity for investors to assess the company's performance in the diabetes care technology sector, where DexCom is a recognized leader.
DexCom (Nasdaq: DXCM) anticipates fourth quarter 2020 revenue of at least $567 million, marking a 23% increase year-over-year. U.S. revenue is projected at approximately $451 million, a 20% rise, while international revenue could reach $116 million, up 33%. For the full fiscal year, revenue is expected to be around $1.925 billion, over 30% growth compared to 2019. Looking ahead, DexCom projects 2021 revenue of $2.21 billion to $2.31 billion, a growth of 15% to 20%, driven by sensor volume increases and international expansion.
DexCom (NASDAQ:DXCM) announces that CEO Kevin Sayer will present an update at the 39th annual J.P. Morgan Healthcare Conference on January 11, 2021. The virtual presentation is set to begin at approximately 11:40 AM EST and will be available via a concurrent webcast.
Investors can access the webcast link through the Dexcom IR website under 'Events and Presentations.' DexCom is recognized for its innovative continuous glucose monitoring (CGM) systems, aiding diabetes management globally.
DexCom, Inc. (NASDAQ:DXCM) has announced management presentations at two upcoming virtual investor conferences. Steve Pacelli, Executive Vice President of Strategy and Corporate Development, will present at the Stifel Virtual Healthcare Conference on November 16, 2020, at 11:20 AM (EST) and at the Piper Sandler Healthcare Conference on December 1, 2020, at 3:00 PM (EST). Webcasts of these events will be available on the Dexcom Investor Relations website, where they will also be archived for future access.
DexCom, Inc. (NASDAQ:DXCM) will host an Investor Day on December 9, from 8:30 AM to 11:30 AM PST. The virtual event will feature presentations from management and industry leaders discussing market opportunities, business strategy, and long-term financial outlook.
The webcast will be available without pre-registration, accessible at dexcom2020investorday.com, and a replay will follow shortly after the event concludes.
DexCom, Inc. (NASDAQ:DXCM) will host an Investor Day on December 9, from 8:30 AM to 11:30 AM PST. The event will be virtual and feature presentations from management and industry leaders discussing the company’s market opportunities, business strategy, innovation, and long-term financial outlook. A live webcast will be available without pre-registration at dexcom2020investorday.com. A replay will be accessible shortly after the event concludes.
DexCom, Inc. (Nasdaq: DXCM) reported a robust 26% revenue growth in Q3 2020, reaching $500.9 million, driven by a 29% increase in U.S. sales and a 17% rise in international revenue. GAAP operating income was $94.1 million, reflecting an 18.8% operating margin, up 470 basis points year-over-year. The company raised its full-year revenue guidance to approximately $1.9 billion, indicating 29% growth. Notable highlights include the establishment of a CGM outcomes registry and a Patient Assistance Program for those affected by COVID-19. Cash reserves stand at $2.60 billion, ensuring financial flexibility.
DexCom, a leader in diabetes care technology, announced the retirement of Rick Doubleday, EVP and CCO, effective 2020, after significant contributions since 2009. Under his leadership, DexCom achieved $500.9 million in revenue for Q3 2020, marking a 26% growth year-over-year. Doubleday will continue as a consultant to aid the company's growth initiatives. The company plans to present its financial results on October 27, 2020. DexCom remains committed to enhancing diabetes management through innovative glucose monitoring systems.
DexCom, Inc. (NASDAQ: DXCM) has appointed Kyle Malady to its Board of Directors, effective immediately. Malady currently serves as executive vice president and chief technology officer at Verizon, overseeing global network operations and IT functions. With over 30 years of experience in mobile communications technology, Malady's extensive background is expected to enhance DexCom's leadership in continuous glucose monitoring and data analytics. His appointment aims to bolster DexCom’s efforts to empower diabetes management.
FAQ
What is the current stock price of DexCom (DXCM)?
What is the market cap of DexCom (DXCM)?
What does DexCom, Inc. specialize in?
When was DexCom, Inc. founded?
What are some of DexCom's key products?
How do DexCom's CGM systems benefit diabetic patients?
What recent achievements has DexCom made?
How is DexCom integrating its CGM systems with other technologies?
What is the significance of DexCom's strategic partnerships?
What is DexCom's approach to innovation?
How does DexCom support the community?
What financial trends are seen in DexCom's performance?
